Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases

Cancer

Volumn 119, Issue 15, 2013, Pages 2778-2788

  Brouquet, Antoine ^a   Zimmitti, Giuseppe ^b   Kopetz, Scott ^b   Stift, Judith ^c   Julié, Catherine ^a   Lemaistre, Anne Isabelle ^d   Agarwal, Atin ^e   Patel, Viren ^b   Benoist, Stephane ^a   Nordlinger, Bernard ^a   Gandini, Alessandro ^d   Rivoire, Michel ^d   Stremitzer, Stefan ^c   Gruenberger, Thomas ^c   Vauthey, Jean Nicolas ^b   Maru, Dipen M ^b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b UNIVERSITY OF TEXAS   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d CENTRE LÉON BÉRARD   (France)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

colorectal liver metastases; preoperative chemotherapy; Avastin; survival; pathology response; validation; multicenter study; tumor regression; tumor normal liver interface

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; COLORECTAL LIVER METASTASIS; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER NODULE; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; ONCOLOGICAL PARAMETERS; PATHOLOGIST; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TUMOR CELL; TUMOR NORMAL LIVER INTERFACE; TUMOR VOLUME; VALIDATION STUDY;

COLORECTAL LIVER METASTASES; PREOPERATIVE CHEMOTHERAPY; AVASTIN; SURVIVAL; PATHOLOGY RESPONSE; VALIDATION; MULTICENTER STUDY; TUMOR REGRESSION; TUMOR-NORMAL LIVER INTERFACE;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES;

EID: 84880571481     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28097     Document Type: Article

References (22)

1. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230: 309-318.
2. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371: 1007-1016.
3. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010; 11: 38-47.
4. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27: 3677-3683.
5. Andreou A, Aloia TA, Brouquet et al. Recent advances in treatment of colorectal liver metastases. Gastrointest Cancer Res 2011; 4 (4 suppl 1): S2-S8.
6. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004; 239: 818-825.
7. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG,. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008; 247: 125-135.
8. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009; 250: 440-448.
9. Prowell T, Pazdur R,. Pathologic complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012; 366: 2438-2441.
10. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003; 7: 109-115.
11. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007; 18: 299-304.
12. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008; 26: 1635-1641.
13. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008; 26: 5344-5351.
14. Maru DM, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010; 34: 1287-1294.
15. Poultsides GA, Bao F, Servais EL, et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol. 2012; 19: 2797-2804
16. Chun YS, Vauthey JN, Boonsirikamchi P, et al. Association of computed tomography criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009; 302: 2338-2344.
17. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant therapy. J Clin Oncol. 2007; 25: 4414-4422.
18. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103: 1347-1355.
19. Rodel C, Martus P, Papdoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy in rectal cancer. J Clin Oncol. 2006; 23: 8688-8696.
20. Ghadimi BM, Grade M, Difilippantonio MJ, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol. 2005; 23: 1826-1838.
21. Thuerigen O, Schneeweiss A, Toeds G, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol. 2006; 24: 1839-1845.
22. Klinger M, Tamandi D, Eipeldauer S, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010; 17: 2059-2065.